Home/Pipeline/Idylla SARS-CoV-2 Test

Idylla SARS-CoV-2 Test

COVID-19

ApprovedCE-IVD

Key Facts

Indication

COVID-19

Phase

Approved

Status

CE-IVD

Company

Biocartis

About Biocartis

Founded in 2007, Biocartis has established itself as a leader in automated, rapid molecular diagnostics with its proprietary Idylla™ platform. Its core mission is to make molecular testing actionable, easy, fast, and suitable for any lab, thereby enabling personalized medicine worldwide. Key achievements include securing FDA approval for its Idylla MSI Test and building a broad menu of RUO and IVD assays, primarily in oncology. The company's strategy revolves around expanding its test menu, deepening market penetration in the US and Europe, and leveraging partnerships to drive platform adoption.

View full company profile

Therapeutic Areas

Oncology Infectious Diseases

Other COVID-19 Drugs

Drug	Company	Phase	Status
COVID-19 Severity Prediction Test	Age Labs	Development	Active
PanCytoVir™ (oral probenecid)	TrippBio	Phase 2	Active
OT-101	Sapu BioScience	Clinical Trial (Phase not specified)	Active
COVID-19 Vaccine Testing (for AstraZeneca)	Advaxia Biologics	Approved	Active
COVID-19 Vaccine Clinical Batches	Advaxia Biologics	Clinical	Active
UOL COVID-19 Test	Uh-Oh Labs	Approved	Active
Lagevrio (molnupiravir)	Ridgeback Biotherapeutics	Approved/EUA	Active
CVXGA	CyanVac	Phase 2	Active
SARS-CoV-2 Test	NanoPin Technologies	Commercial (LDT)	Active
Emeramide for COVID-19	EmeraMed	Preclinical	Active
COVID-19 Oral Therapeutic (with Sen-Jam Pharmaceutical)	KVK Tech	Development	Active
Extraction-Free COVID-19 RT-PCR Kit	Pharmozyme	Commercial	Active